GS-5759, a Bifunctional β2-Adrenoceptor Agonist and Phosphodiesterase 4 Inhibitor for Chronic Obstructive Pulmonary Disease with a Unique Mode of Action: Effects on Gene Expression in Human Airway Epithelial Cells

(R)-6-[(3-{[4-(5-{[2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino}pent-1-yn-1-yl)phenyl] carbamoyl}phenyl)sulphonyl]-4-[(3-methoxyphenyl)amino]-8-methylquinoline-3-carboxamide trifluoroacetic acid (GS-5759) is a bifunctional ligand composed of a quinolinone-containing pharmacophore [β2-adrenoceptor agonist orthostere (β2A)] found in several β2-adrenoceptor agonists, including indacaterol, linked covalently to a phosphodiesterase 4 (PDE4) inhibitor related to 6-[3-(dimethylcarbamoyl)benzenesulphonyl]-4-[(3-methoxyphenyl)amino]-8-methylquinoline-3-carboxamide (GSK 256066) by a pent-1-yn-1-ylbenzene spacer. GS-5759 had a similar affinity for PDE4B1 and the native β2-adrenoceptor expressed on BEAS-2B human airway epithelial cells. However, compared with the monofunctional parent compound, β2A, the KA of GS-5759 for the β2-adrenoceptor was 35-fold lower. Schild analysis determined that the affinities of the β-adrenoceptor antagonists, (2R,3R)-1-[(2,3-dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl) amino]-2-butanol (ICI 118551) and propranolol, were agonist-dependent, being significantly lower for GS-5759 than β2A. Collectively, these data can be explained by “forced proximity,” bivalent binding where the pharmacophore in GS-5759 responsible for PDE4 inhibition also interacts with a nonallosteric domain within the β2-adrenoceptor that enhances the affinity of β2A for the orthosteric site. Microarray analyses revealed that, after 2-hour exposure, GS-5759 increased the expression of >3500 genes in BEAS-2B cells that were highly rank-order correlated with gene expression changes produced by indacaterol and GSK 256066 in combination (Ind/GSK). Moreover, the line of regression began close to the origin with a slope of 0.88, indicating that the magnitude of most gene expression changes produced by Ind/GSK was quantitatively replicated by GS-5759. Thus, GS-5759 is a novel compound exhibiting dual β2-adrenoceptor agonism and PDE4 inhibition with potential to interact on target tissues in a synergistic manner. Such polypharmacological behavior may be particularly effective in chronic obstructive pulmonary disease and other complex disorders where multiple processes interact to promote disease pathogenesis and progression.

[1]  Christopher Southan,et al.  The Concise Guide to PHARMACOLOGY 2015/16: G protein‐coupled receptors , 2015, British journal of pharmacology.

[2]  A. Ammit,et al.  Inhibitors of Phosphodiesterase 4, but Not Phosphodiesterase 3, Increase β2-Agonist-Induced Expression of Antiinflammatory Mitogen-Activated Protein Kinase Phosphatase 1 in Airway Smooth Muscle Cells. , 2015, American journal of respiratory cell and molecular biology.

[3]  M. Johnson,et al.  The long‐acting β2‐adrenoceptor agonist, indacaterol, enhances glucocorticoid receptor‐mediated transcription in human airway epithelial cells in a gene‐ and agonist‐dependent manner , 2015, British journal of pharmacology.

[4]  R. Campbell,et al.  Repurposing Human PDE4 Inhibitors for Neglected Tropical Diseases. Evaluation of Analogs of the Human PDE4 Inhibitor GSK‐256066 as Inhibitors of PDEB1 of Trypanosoma brucei , 2015, Chemical biology & drug design.

[5]  M. Johnson,et al.  An analysis of glucocorticoid receptor‐mediated gene expression in BEAS‐2B human airway epithelial cells identifies distinct, ligand‐directed, transcription profiles with implications for asthma therapeutics , 2015, British journal of pharmacology.

[6]  M. Mammen,et al.  Discovery of (R)-1-(3-((2-chloro-4-(((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)amino)-3-oxopropyl)piperidin-4-yl [1,1'-biphenyl]-2-ylcarbamate (TD-5959, GSK961081, batefenterol): first-in-class dual pharmacology multivalent muscarinic antagonist and β , 2015, Journal of medicinal chemistry.

[7]  P. Montuschi,et al.  Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends. , 2015, Journal of medicinal chemistry.

[8]  C. Montón,et al.  Roflumilast added to triple therapy in patients with severe COPD: a real life study. , 2015, Pulmonary pharmacology & therapeutics.

[9]  R. Newton,et al.  Superiority of Combined Phosphodiesterase PDE3/PDE4 Inhibition over PDE4 Inhibition Alone on Glucocorticoid- and Long-Acting β2-Adrenoceptor Agonist–Induced Gene Expression in Human Airway Epithelial Cells , 2015, Molecular Pharmacology.

[10]  J. McDonald,et al.  The in vivo efficacy and side effect pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long-acting β2-adrenoceptor agonist in preclinical animal species , 2014, Pharmacology research & perspectives.

[11]  P. Parizel,et al.  The effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients , 2014, European Respiratory Journal.

[12]  M. Salmon,et al.  The In Vitro Pharmacology of GS-5759, A Novel Bifunctional Phosphodiesterase 4 Inhibitor and Long Acting β2-Adrenoceptor Agonist , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[13]  R. Newton,et al.  How phosphodiesterase 4 inhibitors work in patients with chronic obstructive pulmonary disease of the severe, bronchitic, frequent exacerbator phenotype. , 2014, Clinics in chest medicine.

[14]  D. Siderovski,et al.  Induction of Regulator of G-Protein Signaling 2 Expression by Long-Acting β2-Adrenoceptor Agonists and Glucocorticoids in Human Airway Epithelial Cells , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[15]  P. Norman.  New dual-acting bronchodilator treatments for COPD, muscarinic antagonists and β2 agonists in combination or combined into a single molecule , 2013, Expert opinion on investigational drugs.

[16]  E. Bateman,et al.  Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD. , 2013, Pulmonary pharmacology & therapeutics.

[17]  S. Greer,et al.  Concurrent Agonism of Adenosine A2B and Glucocorticoid Receptors in Human Airway Epithelial Cells Cooperatively Induces Genes with Anti-Inflammatory Potential: A Novel Approach to Treat Chronic Obstructive Pulmonary Disease , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[18]  S. Farrow,et al.  Discovery of GW870086: a potent anti‐inflammatory steroid with a unique pharmacological profile , 2013, British journal of pharmacology.

[19]  Tomoaki Koga,et al.  Inhibition of PDE4B suppresses inflammation by increasing expression of the deubiquitinase CYLD , 2013, Nature Communications.

[20]  S. Charlton,et al.  Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands , 2013, British journal of pharmacology.

[21]  R. Newton,et al.  Phosphodiesterase 4 Inhibitors Augment the Ability of Formoterol to Enhance Glucocorticoid-Dependent Gene Transcription in Human Airway Epithelial Cells: A Novel Mechanism for the Clinical Efficacy of Roflumilast in Severe Chronic Obstructive Pulmonary Disease , 2013, Molecular Pharmacology.

[22]  J. Riley,et al.  A new class of bronchodilator improves lung function in COPD: a trial with GSK961081 , 2013, European Respiratory Journal.

[23]  C. Robinson,et al.  Nonhuman targets in allergic lung conditions. , 2013, Future medicinal chemistry.

[24]  M. Mammen,et al.  Preclinical efficacy of THRX-200495, a dual pharmacology muscarinic receptor antagonist and β(2)-adrenoceptor agonist (MABA). , 2012, Pulmonary pharmacology & therapeutics.

[25]  J. Gobburu,et al.  Limitations of model based dose selection for indacaterol in patients with chronic obstructive pulmonary disease. , 2012, International journal of clinical pharmacology and therapeutics.

[26]  P. Sexton,et al.  The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-coupled receptors. , 2012, Annual review of pharmacology and toxicology.

[27]  S. Heximer,et al.  β2-Adrenoceptor agonist-induced RGS2 expression is a genomic mechanism of bronchoprotection that is enhanced by glucocorticoids , 2011, Proceedings of the National Academy of Sciences.

[28]  L. Jones,et al.  Dual-pharmacology muscarinic antagonist and β₂ agonist molecules for the treatment of chronic obstructive pulmonary disease. , 2011, Future medicinal chemistry.

[29]  N. Holden,et al.  Inflammatory Stimuli Inhibit Glucocorticoid-Dependent Transactivation in Human Pulmonary Epithelial Cells: Rescue by Long-Acting β2-Adrenoceptor Agonists , 2011, Journal of Pharmacology and Experimental Therapeutics.

[30]  P. Scammells,et al.  Design Strategies for Bivalent Ligands Targeting GPCRs , 2011, ChemMedChem.

[31]  Richard Graham Knowles,et al.  GSK256066, an Exceptionally High-Affinity and Selective Inhibitor of Phosphodiesterase 4 Suitable for Administration by Inhalation: In Vitro, Kinetic, and In Vivo Characterization , 2011, Journal of Pharmacology and Experimental Therapeutics.

[32]  M. Mammen,et al.  THRX-198321 Is a Bifunctional Muscarinic Receptor Antagonist and β2-Adrenoceptor Agonist (MABA) That Binds in a Bimodal and Multivalent Manner , 2011, Molecular Pharmacology.

[33]  M. Mammen,et al.  Discovery of muscarinic acetylcholine receptor antagonist and beta 2 adrenoceptor agonist (MABA) dual pharmacology molecules. , 2011, Bioorganic & medicinal chemistry letters.

[34]  A. Hatzelmann,et al.  The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. , 2010, Pulmonary pharmacology & therapeutics.

[35]  S. Field,et al.  Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD , 2010, Drug design, development and therapy.

[36]  R. Iyengar,et al.  Systems approaches to polypharmacology and drug discovery. , 2010, Current opinion in drug discovery & development.

[37]  Richard M Myers,et al.  Genomic determination of the glucocorticoid response reveals unexpected mechanisms of gene regulation. , 2009, Genome research.

[38]  F. Martinez,et al.  Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials , 2009, The Lancet.

[39]  J. Chivers,et al.  Long-Acting β2-Adrenoceptor Agonists Synergistically Enhance Glucocorticoid-Dependent Transcription in Human Airway Epithelial and Smooth Muscle Cells , 2008, Molecular Pharmacology.

[40]  Terry Kenakin,et al.  Allosteric Theory: Taking Therapeutic Advantage of the Malleable Nature of GPCRs , 2007, Current neuropharmacology.

[41]  J. Fozard,et al.  In Vitro and in Vivo Pharmacological Characterization of 5-[(R)-2-(5,6-Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (Indacaterol), a Novel Inhaled β2 Adrenoceptor Agonist with a 24-h Duration of Action , 2006, Journal of Pharmacology and Experimental Therapeutics.

[42]  R. Morphy,et al.  Designed multiple ligands. An emerging drug discovery paradigm. , 2005, Journal of medicinal chemistry.

[43]  P. Barnes,et al.  Differential effects of RU486 reveal distinct mechanisms for glucocorticoid repression of prostaglandin E release. , 2004, European journal of biochemistry.

[44]  A. Christopoulos,et al.  Fitting Models to Biological Data Using Linear and Nonlinear Regression: A Practical Guide to Curve Fitting , 2004 .

[45]  P. Barnes,et al.  Adenovirus-Mediated Delivery and Expression of a cAMP-Dependent Protein Kinase Inhibitor Gene to BEAS-2B Epithelial Cells Abolishes the Anti-Inflammatory Effects of Rolipram, Salbutamol, and Prostaglandin E2: A Comparison with H-89 , 2004, Journal of Pharmacology and Experimental Therapeutics.

[46]  K. Rabe,et al.  Does a single dose of the phosphodiesterase 4 inhibitor, cilomilast (15 mg), induce bronchodilation in patients with chronic obstructive pulmonary disease? , 2003, Pulmonary pharmacology & therapeutics.

[47]  G. Whitesides,et al.  Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors. , 1998, Angewandte Chemie.

[48]  D. Dennis,et al.  Irreversible binding of a carbostyril‐based agonist and antagonist to the β‐adrenoceptor in DDT1 MF‐2 cells and rat aorta , 1998, British journal of pharmacology.

[49]  R. Owens,et al.  Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3. , 1997, The Biochemical journal.

[50]  Robert A. Copeland,et al.  Estimating KI values for tight binding inhibitors from dose-response plots , 1995 .

[51]  M. Giembycz,et al.  Putative substrates for cyclic nucleotide-dependent protein kinases and the control of airway smooth muscle tone. , 1991, Journal of autonomic pharmacology.

[52]  G. Martin,et al.  Estimation of agonist affinity and efficacy by direct, operational model-fitting. , 1990, Journal of pharmacological methods.

[53]  K. Standifer,et al.  Carbostyril Derivatives Having Potent β-Adrenergic Agonist Properties. , 1988 .

[54]  K. Standifer,et al.  Carbostyril derivatives having potent beta-adrenergic agonist properties. , 1987, Journal of medicinal chemistry.

[55]  J. Black,et al.  Operational models of pharmacological agonism , 1983, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[56]  D. Waud,et al.  Kinetic and empirical analysis of dose-response curves illustrated with a cardiac example. , 1978, Life sciences.

[57]  Y. Yabuuchi,et al.  Sympathomimetic amines having a carbostyril nucleus. , 1976, Journal of medicinal chemistry.

[58]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[59]  J. Mestres,et al.  On the origins of drug polypharmacology , 2013 .

[60]  N. Nasreen,et al.  Fluticasone propionate and Salmeterol combination induces SOCS-3 expression in airway epithelial cells. , 2012, International immunopharmacology.

[61]  G. Phillips,et al.  Bifunctional Compounds for the Treatment of COPD , 2012 .

[62]  T. Steinfeld,et al.  Multivalent dual pharmacology muscarinic antagonist and β₂ agonist (MABA) molecules for the treatment of COPD. , 2012, Progress in medicinal chemistry.

[63]  Tony W Dean,et al.  Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration. , 2009, Bioorganic & medicinal chemistry letters.

[64]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[65]  K. Chung,et al.  Effect of (cid:1) 2 -adrenoceptor agonists and other cAMP-elevating agents on inflammatory gene expression in human ASM cells: a role for protein kinase A , 2008 .

[66]  C. Llewellyn-Jones.  Long-acting β2-agonists in chronic obstructive pulmonary disease , 2002 .

[67]  C. Stratowa,et al.  Functional testing of human dopamine D1 and D5 receptors expressed in stable cAMP-responsive luciferase reporter cell lines. , 1993, Journal of receptor research.